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Integrating Neglected Tropical Diseases control
programs: successes and challenges
A. Garba
RISEAL Niger, Niamey, Niger
Africa bears a disproportionately high burden of NTDs, which
affects more than one billion people worldwide. About 50% of
this burden occurs in Africa. Preventive Chemotherapy (PCT) is
a major intervention toward reducing the burden of neglected
tropical diseases (NTDs). Themajor NTDs targeted for PCT are Lym-
phatic Filariasis, Onchocerciasis, Schistosomiasis, Soil-Transmitted
Helminthiasis and Trachoma. Integration is a cost effective strategy
to scale up intervention toward control and elimination of NTDS
in order to achieve the goals set by World Health Organization
(WHO) roadmap for control and elimination ofNTDs. Integration of
preventive chemotherapy which mean joint distribution of drugs
can optimize the use of resources and accelerate the achievement
of the targets set for elimination. To assist the implementation
of this strategy, the WHO published a guidelines document enti-
tled “Preventive chemotherapy in human helminthiasis” in 2006.
The guidelines direct programme managers on how to effectively
coordinate theuseofdrugs.Despite theobviousbeneﬁts, the imple-
mentation of integrated NTD in Africa Region has been generally
poor as well as the rate of progress in scaling up the interventions
to tackle theNTDs. Several challenges need to be addressed in order
to achieve the necessary expansion of NTD control/elimination
interventions in the African Region. These include mainly the inad-
equatemanagement capacity andcoordinationofNTDpartners and
the insufﬁcient leadership and resources allocated by the endemic
countries for NTD activities.
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Pathways to HIV cure
D. Persaud
Johns Hopkins Children’s Center, Baltimore, MD, USA
Combination antiretroviral therapy (cART) is effective in
suppressing HIV replication in infected individuals, leading to
undetectable plasma levels by standard clinical assays. However,
a latent HIV reservoir in resting memory CD4+ T cells is established
that renders infection incurable. Within weeks of stopping ther-
apy, patients experience rebound plasma viremia to pretreatment
levels. Identifying strategies to prevent rebound viremia following
cessation of treatment, deﬁned as HIV remission or “cure”, is a cur-
rent focus of HIV therapeutics. The example of the “Berlin Patient”,
who achieved HIV remission following stem cell transplantation
with donor cells homozygous for the chemokine receptor 5 (CCR5)
delta 32, demonstrated that HIV reservoirs can be cleared sufﬁ-
ciently to prevent rebound viremia. In the case of the “Mississippi
Child”, initiation of cART by 31hours of age appeared to have
curtailed formation of long-lived HIV reservoirs to the point that
cART for 18 months was sufﬁcient to sustain HIV remission during
an additional 18 months of follow-up. Concluding that very early
cART likely led to HIV remission in the “Mississippi Child” required
detailed knowledge and analyses of thedynamics ofHIV replication
in the infant, knowledge of HIV reservoir dynamics and immune
markers of HIV persistence, and understanding characteristics of
the neonatal immune system that impact HIV reservoir formation.
Strategies that are under investigation to assess HIV remission or
cure, including very early treatment in perinatal infection will be
discussed.
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Chronic inﬂammation and its role in HIV
pathogenesis
P. Hunt
UCSF School of Medicine, San Francisco, CA, USA
Persistent immune activation and inﬂammation has emerged
as a major challenge of the modern HIV treatment era. While
immune activation, inﬂammatory, and coagulation markers typi-
cally decline during suppressive antiretroviral therapy (ART), they
remain abnormally elevated in many HIV-infected individuals
and predict subsequent mortality as well as several non-AIDS
comorbidities like cardiovascular disease, cancer, diabetes, and
neurocognitive dysfunction. The goal of the current lecture is
to summarize the current state of our knowledge regarding the
underlying causes of persistent immune activation during ART-
mediated viral suppression as well as the link between persistent
immune activation and morbidity and mortality in this setting.
Several recent studies have linked surrogatemarkers of this persis-
tent inﬂammatory state to clinical outcomes, validating persistent
immuneactivationas aviable therapeutic target.Other recent stud-
ies have helped clarify the roles of persistent HIV expression and/or
replication, microbial translocation, and co-infections in driving
this persistent inﬂammatory state, identifying speciﬁc targets for
novel interventions. Lastly, some commonly used medications
with anti-inﬂammatory properties have recently been shown to
decrease immune activation in this setting and may hold promise
in future clinical event trials.
http://dx.doi.org/10.1016/j.ijid.2014.03.507
